NASDAQ:LPTX - Leap Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.65 -0.01 (-0.60 %)
(As of 02/18/2019 08:12 AM ET)
Previous Close$1.66
Today's Range$1.60 - $1.68
52-Week Range$1.35 - $10.25
Volume762,410 shs
Average Volume517,675 shs
Market Capitalization$24.26 million
P/E Ratio-0.50
Dividend YieldN/A
Beta2.45
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.90 per share

Profitability

Net Income$-29,720,000.00

Miscellaneous

Employees22
Market Cap$24.26 million
OptionableNot Optionable

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) announced its earnings results on Thursday, November, 15th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.02. View Leap Therapeutics' Earnings History.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 22nd 2019. View Earnings Estimates for Leap Therapeutics.

What price target have analysts set for LPTX?

2 brokers have issued 12 month target prices for Leap Therapeutics' shares. Their predictions range from $8.00 to $13.00. On average, they anticipate Leap Therapeutics' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 536.4% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

What is the consensus analysts' recommendation for Leap Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

What are Wall Street analysts saying about Leap Therapeutics stock?

Here are some recent quotes from research analysts about Leap Therapeutics stock:
  • 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (1/16/2019)
  • 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)

Has Leap Therapeutics been receiving favorable news coverage?

Headlines about LPTX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Leap Therapeutics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of Leap Therapeutics' key competitors?

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the folowing people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)
  • Dr. Cynthia A. Sirard, VP of Clinical Devel.
  • Mr. Mark O'Mahony, VP of Manufacturing

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.09%). Company insiders that own Leap Therapeutics stock include Augustine Lawlor and Christopher Mirabelli. View Institutional Ownership Trends for Leap Therapeutics.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Leap Therapeutics stock in the last two years include Augustine Lawlor and Christopher Mirabelli. View Insider Buying and Selling for Leap Therapeutics.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $1.65.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $24.26 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is http://www.leaptx.com.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel